BACKGROUND: This study aimed to develop a noninvasive orthotopic model for metastasis of colon and rectal cancer using a transanal approach. Currently, the most accurate orthotopic representation of metastatic human colon cancer is via a cecal injection. The transanal model allows for further examination of systemic immune responses, tumor take, and onset of metastasis without prior surgical intervention. METHODS: For this study, 60 Balb/c mice were anesthetized and subjected to gentle anal dilation using blunt-tipped forceps at the anal opening. Murine colon cancer parental CT26 or luciferase-labeled CT26 (CT26-luc) cells were injected submucosally into the distal posterior rectum (30 CT26 and 30 CT26 injections) at concentrations of 2.5 x 10(4), 1 x 10(5), and 1 x 10(6) in a volume of 50 microl. Tumor growth and metastatic development was monitored at 5-day intervals for 50 days. All the remaining mice were killed on postinjection day 50. RESULTS: The optimal concentration for metastasis and survival of the mice was 2.5 x 10(4) cells. Higher concentrations of cells yielded higher mortality but did not result in metastasis. The overall success of tumor growth in both experiments using the transanal rectal injection was 65%. Histology showed that all tumors were poorly differentiated adenocarcinomas. Two mice (3.3%) from the 2.5 x 10(4) CT26-luc group showed metastatic colonic adenocarcinoma to the liver on postinjection day 50. CONCLUSION: Transanal rectal injection of colon cancer cells offers a nonoperative orthotopic murine model for colon cancer that may lead to the development of metastasis. By using an orthotopic model, more aspects of metastatic colon cancer can be evaluated without the influence of a previous abdominal incision. These results warrant more investigation.
BACKGROUND: This study aimed to develop a noninvasive orthotopic model for metastasis of colon and rectal cancer using a transanal approach. Currently, the most accurate orthotopic representation of metastatic humancolon cancer is via a cecal injection. The transanal model allows for further examination of systemic immune responses, tumor take, and onset of metastasis without prior surgical intervention. METHODS: For this study, 60 Balb/c mice were anesthetized and subjected to gentle anal dilation using blunt-tipped forceps at the anal opening. Murinecolon cancer parental CT26 or luciferase-labeled CT26 (CT26-luc) cells were injected submucosally into the distal posterior rectum (30 CT26 and 30 CT26 injections) at concentrations of 2.5 x 10(4), 1 x 10(5), and 1 x 10(6) in a volume of 50 microl. Tumor growth and metastatic development was monitored at 5-day intervals for 50 days. All the remaining mice were killed on postinjection day 50. RESULTS: The optimal concentration for metastasis and survival of the mice was 2.5 x 10(4) cells. Higher concentrations of cells yielded higher mortality but did not result in metastasis. The overall success of tumor growth in both experiments using the transanal rectal injection was 65%. Histology showed that all tumors were poorly differentiated adenocarcinomas. Two mice (3.3%) from the 2.5 x 10(4) CT26-luc group showed metastatic colonic adenocarcinoma to the liver on postinjection day 50. CONCLUSION: Transanal rectal injection of colon cancer cells offers a nonoperative orthotopic murine model for colon cancer that may lead to the development of metastasis. By using an orthotopic model, more aspects of metastatic colon cancer can be evaluated without the influence of a previous abdominal incision. These results warrant more investigation.
Authors: María Virtudes Céspedes; Carolina Espina; Miguel Angel García-Cabezas; Manuel Trias; Alicia Boluda; María Teresa Gómez del Pulgar; Francesc Josep Sancho; Manuel Nistal; Juan Carlos Lacal; Ramon Mangues Journal: Am J Pathol Date: 2007-03 Impact factor: 4.307
Authors: R L Whelan; M Franklin; S D Holubar; J Donahue; R Fowler; C Munger; J Doorman; J E Balli; J Glass; J-J Gonzalez; M Bessler; H Xie; M Treat Journal: Surg Endosc Date: 2003-03-19 Impact factor: 4.584
Authors: Heidi Nelson; Daniel J Sargent; H Sam Wieand; James Fleshman; Mehran Anvari; Steven J Stryker; Robert W Beart; Michael Hellinger; Richard Flanagan; Walter Peters; David Ota Journal: N Engl J Med Date: 2004-05-13 Impact factor: 91.245
Authors: R L Whelan; J D Allendorf; C N Gutt; C A Jacobi; D Mutter; H R Dorrance; M Bessler; H J Bonjer Journal: Surg Endosc Date: 1998-08 Impact factor: 4.584
Authors: Melissa Donigan; Laurie S Norcross; John Aversa; Jimmie Colon; Joshua Smith; Rafael Madero-Visbal; Shuan Li; Neal McCollum; Andrea Ferrara; Joseph T Gallagher; Cheryl H Baker Journal: J Surg Res Date: 2008-06-20 Impact factor: 2.192
Authors: Ulrich Bork; Robert Grützmann; Nuh N Rahbari; Sebastian Schölch; Marius Distler; Christoph Reissfelder; Moritz Koch; Jürgen Weitz Journal: World J Gastroenterol Date: 2014-08-14 Impact factor: 5.742
Authors: Maria Felicia Fiordelisi; Carlo Cavaliere; Luigi Auletta; Luca Basso; Marco Salvatore Journal: J Clin Med Date: 2019-11-06 Impact factor: 4.241
Authors: Mihály Balogh; Jixiang Zhang; Caitlyn M Gaffney; Neha Kalakuntla; Nicholas T Nguyen; Ronnie T Trinh; Clarissa Aguilar; Hoang Vu Pham; Bojana Milutinovic; James M Nichols; Rajasekaran Mahalingam; Andrew J Shepherd Journal: J Neuroinflammation Date: 2022-08-12 Impact factor: 9.587